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THROW ME A BONE MARROW TRANSPLANT: PERIPHERAL
BLOOD STEM CELLS AND THE NATIONAL ORGAN
TRANSPLANT ACT
Noel Barnard*
Thousands ofpeople die every year in the United States waiting for
a matching bone marrow donor. This is attributed to a shortage of
willing donors. One solution that has been suggested is to
incentivize donation with compensation. However, since 1984, the
National Organ Transplant Act has made it illegal for anyone in
the United States to provide compensation for organ donation,
including bone marrow. Still, changes in the way bone marrow
transplants are performed have prompted proponents of organ
donor compensation to challenge the law's application to this
procedure. In Flynn v. Holder, the Ninth Circuit ruled that the
federal ban on compensation did not apply to bone marrow
donation performed by stem cell transplant. This Recent
Development argues that the Ninth Circuit's holding is less likely
to be overturned on appeal or through legislation because of its
narrow, straightforward reasoning. In turn, organizations that
compensate marrow donors will be provided with some time to
prove their concept, perhaps changing the minds of opponents.
I. INTRODUCTION
In November 1998, Sue Stein noticed a bulge on the left side of
her stomach.' Not one to make a fuss, Sue said nothing and
continued on with her daily life.2 Several months later, Sue's legs
swelled and her skin became so dry that it bled when she scratched
*J.D. Candidate, University of North Carolina School of Law, 2013. 1 would
like to thank Prof. Joan H. Krause for her guidance, Stefanie M. Gregory for her
editing and input, and the entire NC JOLT staff for their help preparing this
article.
'Sue Stein One Step at a Time, MAYO CLINIc, http://www.mayoclinic.org/
patientstories/story-307.html (last visited Jan. 27, 2012).
2 id
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it.3 Immediately, Sue went to the doctor.' He determined that the
bulge in Sue's stomach was her spleen, which had grown to the
size of a football. ' He diagnosed Sue with non-Hodgkin's
lymphoma, a cancer of the lymphatic system characterized by
tumors derived from white blood cells.' Sue first had her spleen
removed.7 Initially, Sue's cancer responded well. But, the doctor
later determined that Sue would require chemotherapy.' Among
chemotherapy's dangerous side effects is that, along with the
cancer cells, it destroys necessary bone marrow cells. ' The
chemotherapy treatment left Sue with a severely depressed
immune system.o. To restore Sue's lost bone marrow, she required
a transplant from a healthy donor." After testing, Sue's sister was
determined to be the best match. 2
On November 6, 2003, doctors at the Mayo Clinic performed a
stem cell transplant on Sue. 3 The doctors harvested bone marrow
producing stem cells from Sue's sister and injected them into
Sue. 4 This infusion of fresh cells quickly restored Sue's ability to
produce bone marrow." Sue was able to resume a normal life and
has been cancer free to this day.16
Each year, thousands of people find themselves in the same
situation. " While advances in modem medicine like stem cell
transplants have increased donor willingness through decreased
3 id.
4 Id.
5 Id.
6Id.
Id.
9Id
1o Id.
" Id.
12 Id.
13 Id.
14 d.
15 Id.
16id.
'7 THE LEUKEMIA & LYMPHOMA Soc'y, BLOOD AND MARROW STEM CELL
TRANSPLANTATION 9 (2010), available at http://www.l1s.org/content/
nationalcontent/resourcecenter/freeeducationmaterials/treatments/pdf/bloodmarr
owstemcelltransplantation.pdf.
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surgical risk, many people still struggle to find a transplant. "
More than 3,000 people die in the U.S. each year because they
cannot find a suitable marrow donor. 9 Sue was lucky. She was
able to find a match within her own family. Many are not so
fortunate and are forced to rely on a stranger's altruism to save
their lives.
Since 1984, the National Organ Transplantation Act ("NOTA")
has made it illegal to pay someone to donate an organ in the United
States.20 The Ninth Circuit's recent decision in Flynn v. Holder" is
the first to explore the new scientific frontier of stem cell
transplants under NOTA. By holding that stem cell transplants are
not covered by NOTA, the court has opened the door to bone
marrow donor compensation for the first time in the United
States. 22 The court avoided a ruling on broader grounds by
interpreting NOTA narrowly. Because the court avoided an
expansive holding, the likelihood of the decision being overturned
is reduced, whereas a more expansive ruling could have provoked
a backlash.
This Recent Development will explore the court's reasoning in
Flynn and examine its implications for future organ donation
policy. Part II will explore the bone marrow transplant process,
focusing on peripheral blood stem cell transplants and how this
procedure differs from traditional transplantation methods. Part III
will provide a brief overview of organ donor laws, particularly
NOTA. Part IV will analyze the holding of Flynn and the court's
distinction between bone marrow and peripheral blood stem cells.
Finally, Part V will examine the likely effects that a decision
allowing marrow donor compensation will have on patients and
other marrow donation organizations, and ultimately what this
ruling could mean for organ donor compensation generally.
18 Kumud Majumder, Let's Compensate Bone Marrow Donors, USA TODAY
(Feb. 11, 2011, 4:03 PM), http://www.usatoday.com/news/opinion/forum/2011-
02-09-majumder1 1_st_ N.htm.
19 Id.
20 National Organ Transplant Act, 42 U.S.C. § 274e(a) (2006).
21 665 F.3d 1048 (9th Cir. 2011).
22 Id. at 1059.
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II. BONE MARROw TRANSPLANTATION
In order to make sense of the Flynn decision, it is necessary to
understand bone marrow physiology and the technology
underlying the transplant procedure. The distinction between bone
marrow and peripheral blood stem cells is critical to the court's
decision in Flynn. It is also important to understand the current
process for matching donors and recipients because it is central to
comprehending the plaintiffs' concerns about the difficulty of
matching minority race patients.
Bone marrow is the soft, spongy tissue, located inside the
hollow part of certain bones.2 3 It is responsible for forming blood
cells including red blood cells, white blood cells, and platelets.24
These cells carry oxygen, fight infections, clot wounds, and
perform a host of other life-sustaining functions.2 5 Bone marrow
also contains special cells called hematopoietic stem cells. 26
Through a process called differentiation, these cells can develop
into any type of blood cell.27 In a healthy person, stem cells in the
marrow continually differentiate to produce a steady supply of new
blood cells.28
Bone marrow transplants are used to restore proper marrow
function in patients whose marrow has been affected by disease or
injury.29 There are a number of diseases that prompt the need for a
bone marrow transplant.30 These can range from blood cancers,
such as various leukemias and lymphomas, to severe aplastic
anemia." A patient with leukemia or lymphoma often undergoes
23 THE LEUKEMIA & LYMPHOMA SOC'Y, supra note 17, at 5.
24 BE THE MATCH, AN INTRODUCTION TO MARROW AND CORD BLOOD
TRANSPLANT 7 (2011), available at http://marrow.org/Patient/Support
andResources/Resource Library/Learnresources/AnIntroduction to Marrow
and Cord Blood Transplant %28PDF%29.aspx.
25 THE LEUKEMIA & LYMPHOMA Soc'Y, supra note 17, at 4.
26 NAT'L CANCER INST., FACT SHEET: BONE MARROW TRANSPLANTATION
AND PERIPHERAL BLOOD STEM CELL TRANSPLANTATION 1 (2010), available at
http://www.cancer.gov/cancertopics/factsheet/Therapy/fs7 41.pdf.
27 THE LEUKEMIA & LYMPHOMA SOC'Y, supra note 17, at 5.28 d291 d. at 6.
30 BE THE MATCH, supra note 24, at 6.
31 id.
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chemotherapy or radiation, which kills healthy bone marrow along
with cancer cells. 32 A bone marrow transplant is usually the
patient's only hope.33
Once a patient and doctor decide that a bone marrow transplant
is appropriate, the first step is to perform a donor search." Certain
human cells carry a marker called the human leukocyte antigen
("HLA")." This marker lets your immune system know which
cells belong in your body and which do not.36 The HLA proteins
found in an individual's own cells make up that person's tissue
type. While analogous to blood typing, tissue typing is distinct
and more complex." When the immune system recognizes foreign
cells, it responds by attacking them." This is the desired response
when the foreign cell is a virus, but it can be deadly in a transplant
scenario.40 To reduce the chances of adverse immune response,
doctors try to match recipients with donors having the same tissue
type. 4 1
HLA tissue types are inherited genetically with one half
coming from each parent.42 This means that the best place to start
32 Patient Frequently Asked Questions, NAT'L MARROW DONOR PROGRAM,
http://marrow.org/Patient/Support-andResources/Patient FAQs.aspx#types
(last visited Jan. 25, 2012).
33 Id.
34 BE THE MATCH, supra note 24, at 9.
35 THE LEUKEMIA & LYMPHOMA Soc'Y, supra note 17, at 43.
36 BETHE MATCH, supra note 24, at 8.
3 Id.
38 Id.
3 9 Id. at 9.
40 AM. CANCER SOC'Y, STEM CELL TRANSPLANTS (PERIPHERAL BLOOD, BONE
MARROW, AND CORD BLOOD TRANSPLANTS), 9 (2011), available at
http://www.cancer.org/acs/groups/cid/documents/webcontent/003215-pdf.pdf.
With a bone marrow transplant, several conditions can occur as the result of an
adverse immunological response. Id. at 5. The recipient's immune system can
attack the new marrow cells, destroying them before they can begin producing
new blood cells. Id. This is called graft rejection. Id. at 9. On the flipside,
immune cells from the donated marrow can attack the patient. Id. This is called
graft-versus-host-disease (GVHD) and it is one of the most common
complications of bone marrow transplant. Id. at 23. GVHD can vary in
severity, ranging from chronic to acute (life-threatening). Id.
4 'BE THE MATCH, supra note 24, at 8.
42 d
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looking for a suitable matching donor is the recipient's family.43
There is a one in four chance that a sibling with the same parents
will have the same tissue type.4 4 However, nearly seventy percent
of patients are unable to find a suitable donor within their family.4 5
These patients are forced to search for a matching donor using one
of several large donor registries.46 In the United States, the largest
donor registry is the National Marrow Donor Program
("NMDP").4 7 Currently NMDP's Be The Match Registry has
access to over 16.5 million donors and is adding an average of
54,000 donors every month.48
Minorities and individuals of mixed race heritage are much less
likely to find a matching donor because of their diverse genetic
background.49 For example, the Be The Match Registry contains
almost seven million potential white donors.o This compares to
only about 685,000 African-American donors.5 ' NMDP estimates
that the probability that a white person will find a match is 93%.2
For African-Americans, this figure plummets to around 66%."
If a perfect match cannot be found, a donor with a less similar
tissue type can be used.54 However, this reduces the likelihood of
43 id
'* Id.44 Id.
45 Id.
46 AM. CANCER SOC'Y, supra note 40, at 10.47id
48 NAT'L MARROW DONOR PROGRAM, KEY MESSAGES, FACTS & FIGURES, 1
(2012), available at http://marrow.org/workarea/DownloadAsset.aspx?id=l 071.
49 Theodore C. Bergstrom et al., One Chance in a Million: Altruism and the
Bone Marrow Registry, 99 AM. ECON. REV. 1, 2 (2009), available at
http://kelley.iu.edu/BEPP/documents/AERGalleys%5B 1%5D.pdf. The
probability that two randomly selected white Americans will be an HLA match
is less than one in ten thousand, whereas the probability that two randomly
selected African Americans will match is less than one in a hundred thousand.
Id.
5 0 NAT'L MARROW DONOR PROGRAM, supra note 48, at 2.
51 Id.
52 Id. at 3.
s3 Id.
54 See Lee Ann Baxter-Lowe et al., HLA-A Disparities Illustrate Challenges
for Ranking the Impact of HLA Mismatches on Bone Marrow Transplant
Outcomes in the United States, 15 BIOLOGY OF BLOOD AND MARROW
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transplant success." The donor compensation program in Flynn
was motivated largely by this disparity."6
Once a matching donor is identified, the bone marrow can be
transplanted in one of two ways: aspiration or stem cell
apheresis."
A. Bone Marrow Transplant via Aspiration
Originally, bone marrow transplants were accomplished
through a process called aspiration. " Aspiration is a surgical
procedure performed under anesthesia in an operating room." The
doctor inserts a special hollow needle into the bone, usually the
pelvis, and extracts the marrow.60 In a typical procedure, roughly
ten percent, or two pints, of the donor's marrow is collected over a
one to two hour period.6 1 The donor's body typically replaces the
lost bone marrow within four to six weeks.6 2
Once the harvested marrow is processed to remove bone and
blood fragments, it can be given to the recipient. 63 This is done
through an intravenous line, just as the patient would receive a
blood transfusion.' This phase of the transplant usually takes
between one and five hours. 65 The new stem cells know
TRANSPLANTATION 971, 971 (2009) (discussing the potential for establishing
guidelines for the optimal selection of HLA mismatched donors).
5 id.
56 The donor compensation program proposed by plaintiff
MoreMarrowDonors.org is aimed specifically at increasing the supply of donors
with rare cell types. Complaint for Declaratory and Injunctive Relief at 29,
Flynn v. Holder, 665 F.3d 1048 (9th Cir. 2011) (No. 10-55643). Initially, the
donor program would only be open to minorities and mixed-race individuals
because they are more likely to have rare cell types. Id. In the future,
MoreMarrowDonors.org hopes to develop a way to identify rare cell types using
a more accurate proxy than race. Id.
5 NAT'L CANCER INST., supra note 26, at 2-3.
58 Flynn, 665 F.3d at 1051.
59 AM. CANCER SOC'Y, supra note 40, at 11.
60id
61 Id.
62 Id.
63 NAT'L CANCER INST., supra note 26, at 2.
6 Id. at 3.
65 Id.
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automatically where to go once they enter the bloodstream. 66
Within two to four weeks, the new marrow will begin producing
blood cells. " However, complete immune system recovery
typically takes longer, anywhere from several months to two
years."
Marrow donation via aspiration does not typically pose a
substantial risk to the donor.69 The most significant risk stems
from the use of general anesthesia during the procedure. 70
Furthermore, there are usually few side effects from the
procedure. 7' The donor may feel some soreness and stiffness
around the site of the operation, but this will usually subside within
a few days. 72 Some donors also feel tired following the
procedure." Many donors are back to their normal lives within
two to three days.74 Others may require a few weeks to recover.
B. Peripheral Blood Stem Cell Apheresis
Developed in the 1980s, peripheral blood stem cell apheresis
("PBSCA") is now the most common method of bone marrow
transplant.76 According to the Center for International Blood and
Marrow Transplant Research, an estimated 15,800 stem cell
transplants occurred in North America in 2006."
Normally, a small number of hematopoietic stem cells are able
to migrate from the marrow into the bloodstream." These are
called peripheral blood stem cells ("PBSCs").79 Instead of drilling
66 Id. at 4.
67 id.
68 Id.
69 Id. at 3.
70 Id.
71 Id.
72 Id.
* Id74id
75 id
76 Flynn v. Holder, 665 F.3d 1048, 1051 (9th Cir. 2011).
7 THE LEUKEMIA & LYMPHOMA Soc'Y, supra note 17, at 9.
7
1Id. at 17.
79 id.
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into the bone to collect the marrow cells, PBSCA collects the
circulating PBSCs from the blood with a machine. 0
In a healthy person, only a small amount of PBSCs are found
in the bloodstream." To obtain a sufficient number of PBSCs for
transplantation, donors are given drugs that increase the number of
PBSCs for several days prior to donation.8 2 These drugs can have
unpleasant side effects such as nausea, bone pain, and headaches."
These side effects cease once the medication is discontinued.84
PBSC collection begins by placing a catheter in a large vein in
the donor's arm or chest." The donor's blood is withdrawn and
run through an apheresis machine.8 6 This machine separates blood
into its four constituent parts: plasma, red blood cells, white blood
cells, and platelets." The stem cells are contained in the white
blood cell fraction." Accordingly, this fraction is collected while
the rest of the blood is returned to the donor." The process takes
anywhere from two to four hours and is usually done on an
outpatient basis.98 In some instances, the process may be repeated
the next day until a sufficient number of PBSCs are collected."
PBSCA poses very little risk to donors.92 With PBSCA there is
no need for anesthesia or a hospital stay.93 In fact, the process is
less akin to traditional bone marrow transplant ("BMT") and more
like blood or plasma donation.9 4 In addition, the donor's PBSC
levels return to normal almost immediately." The main drawbacks
soId. at 18.
8 Id. at 17.
82 id
83 AM. CANCER SOC'Y, supra note 40, at 12.
84id
85 Id
86 THE LEUKEMIA & LYMPHOMA Soc'Y, supra note 17, at 17.
87 Id.
88 Id.
89 Id.
9o AM. CANCER Soc'Y, supra note 40, at 12.
91 Id
92 See NAT'L CANCER INST., supra note 26, at 3.
SId.
94 Flynn v. Holder, 665 F.3d 1048, 1052 (9th Cir. 2011).
95id.
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of the procedure are the discomfort associated with apheresis and
the side effects of medication given to donors.
III. HISTORY OF ORGAN TRANSPLANT LEGISLATION
The history of organ transplant legislation in the United States
is relatively brief since the technology only became a medical
reality within the last fifty years.9 6 Joseph E. Murray performed
the first successful organ transplant in 1954.97 However, it took
many years before medical advances like HLA-typing and anti-
rejection drugs made transplantation available to a widespread
population.98
As transplants became more prevalent, individual states began
.passing laws regulating the practice." Initially, these laws. tended
to be vague and varied greatly in scope and content."oo By 1968,
six states still had no laws regarding organ transplants and four
states had statutes providing for eye donation only. 1o' The
remaining forty states had donation statutes providing for the
donation of some or all organs.' 2 However, these statutes varied
greatly in their provisions regarding next of kin authority to
donate, donor cards, revocation authority, and conflict of laws."o'
Many legal professionals saw a need to standardize organ donor
practices across the country. 104
The first significant attempt to harmonize organ transplantation
law came, not from Congress, but the National Conference of
96 See UNIV. OF MINN. CTR. FOR BIOETHICS, ETHICS OF ORGAN
TRANSPLANTATION 10 (2004), available at http://www.ahc.umn.edu/img/
assets/26104/OrganTransplantation.pdf
97 Interview by Martin Woolf with Dr. Joseph Murray (May 25, 2004),
available at http://www.donatelifeny.org/uploaded files/tinymce/files/interview
joseph murray.pdf. The first organ to be successfully transplanted was a
kidney donated by the recipient's identical twin. Id.
98 See UNIV. OF MINN. CTR. FOR BIOETHICS, supra note 96, at 10-11.
99 See Alfred M. Sadler Jr. et al., The Uniform Anatomical Gift Act A Model
for Reform, 206 J. AM. MED. 2501, 2501-02 (1968).
1o0 Id
101 Id.
102 id
103 id 
.
'0'See id
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Commissioners on Uniform State Laws (also known as the
Uniform Law Commission, "ULC"). 'O The ULC is an
organization designed to provide "states with non-partisan, well-
conceived and well-drafted legislation that brings clarity and
stability to critical areas of state statutory law."o6 Established in
1892, the ULC is composed of practicing lawyers, judges,
legislators, and law professors "who have been appointed by state
governments ... to research, draft and promote enactment of
uniform state laws in areas of state law where uniformity is
desirable and practical."' 7
Recognizing the need to address issues associated with organ
transplants, the ULC approved the Uniform Anatomical Gift Act
("UAGA") in 1968. '10 The core of the UAGA grants any
individual over eighteen years old the authority to donate all or
part of his body upon death.1 09 The UAGA also provides several
mechanisms for donation, including will, written instrument or
donor card."o The law also limits the ability to accept donations to
"persons or institutions licensed or authorized to practice medicine
and to engage in tissue banking or related matters." n' The
UAGA's provisions make organs more akin to other property
interests." 2 By 1972, all states had adopted some version of the
UAGA."
'0 About the ULC, UNIF. LAW COMM'N, http://uniformlaws.org/
Narrative.aspx?title=About%20the%20ULC (last visited Mar. 10, 2012).
106id
Io7 id.
108 Sadler Jr. et al., supra note 99, at 2501.
1"Id. at 2503.
110 Id.
111 Id.
112 5 ALEXANDER M. CAPRON & FRED H. CATE, TREATISE ON HEALTHCARE
LAW § 21.02 [2] (Matthew Bender & Co. rev. ed. 2011).
113 NAT'L CONFERENCE OF COMM'RS ON UNIF. STATE LAWS, UNIFORM
ANATOMICAL GIFT ACT OF 1987 1 (1987), available at
http://www.law.upenn.edu/bll/archives/ulc/fnact99/uaga87.pdf.
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In 1987 and again in 2006, the UAGA was updated to reflect
changes in transplant technology. 114 These updates aimed to
increase the supply of donor organs to meet the heightened demand
associated with more prevalent transplantation procedures."'
The second piece of legislation to deal with the subject of
organ transplantation was NOTA, passed in 1984.116 The main
feature of NOTA is a blanket prohibition on organ purchases.'
The law states, "[i]t shall be unlawful for any person to knowingly
acquire, receive, or otherwise transfer any human organ for
valuable consideration for use in human transplantation. . . .""
NOTA defines a human organ to include the kidney, liver, heart,
lung, pancreas, bone marrow, cornea, eye, bone, skin, and any
other organ designated by the Secretary of Health and Human
Services ("HHS"). 19 While outright organ purchase is illegal,
NOTA does allow the donor to be paid reasonable expenses
associated with the transplant, such as travel and lost wages. 120
IV. THE FLYNN DECISION
Although the Ninth Circuit has cited NOTA in previous
decisions, prior cases did not engage in statutory interpretation.
For example, in Coyote Publishing, Inc. v. Miller,121 the Ninth
Circuit discussed the state's interest in preventing commodification
of the human body and agreed that such an interest was
legitimate. 122 However, the decision in Flynn is the first to
interpret NOTA and determine whether a particular procedure falls
within the meaning of the law.
1 14 Legislative Fact Sheet-Anatomical Gift Act 2006, UNIF. LAW COMM'N,
http://www.uniformlaws.org/LegislativeFactSheet.aspx?title=Anatomical%20Gi
ft%20Act%20%282006%29 (last visited Mar. 3, 2012).
"' NAT'L CONFERENCE OF COMM'RS ON UNIF. STATE LAWS, supra note 113.
116 National Organ Transplant Act, 42 U.S.C. §§ 273-74 (2006).
117 Id. § 274e(a).
11u Id.
" Id. § 274e(c)(1).
120 Id. §274e(c)(2).
121 598 F.3d 592 (9th Cir. 2010) (discussing the constitutionality of Nevada
state laws restricting the ability of legal brothels to advertise).
122 Id. at 604.
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A. Background
The plaintiffs in Flynn are a diverse group of people, each
involved intimately with the issue of bone marrow
transplantation. 12  Together, they represent the interests of marrow
recipients, medical professionals, and non-profit advocacy
groups. 124 They sought declaratory and injunctive relief from
NOTA's express ban on such a program.125
Doreen Flynn is the mother of three young children afflicted
with a genetic condition called Fanconi anemia.'26 This disease is
rare and causes bone marrow failure, usually in the teen years.127
All three of Flynn's daughters will require a bone marrow
transplant at some point to save their lives. 128 Flynn's oldest
daughter is already experiencing declining blood counts, indicating
that she will need a transplant soon.129
Dr. John Wagner is another plaintiff in this action. 130 His
involvement highlights the concerns of medical professionals on
this issue. In addition to treating patients, Dr. Wagner is the author
of numerous scholarly articles on bone marrow transplant issues
and is an expert in the field."' Dr. Wagner has treated roughly
2,000 patients in need of a bone marrow transplant.'3 2 At least one-
fifth of his patients died because they were unable to find a suitable
donor."' Dr. Wagner admits he has been forced to use donors who
123 Flynn v. Holder, 665 F.3d 1048, 1050 (9th Cir. 2011). There are seven
plaintiffs in total: Doreen Flynn, John Wagner, Mike Hamel, Akiim DeShay,
Mark Hachey, Kamud Majumder, and MoreMarrowDonors.org. Complaint for
Declaratory and Injunctive Relief, supra note 56, at 5. They were represented
by the Institute for Justice, a libertarian public interest law firm. About lJ: Our
Mission, INST. FOR JUSTICE, http://www.ij.org/about (last visited Mar. 10, 2012).
124 Flynn, 665 F.3d at 1051-52.
125 Id. at 1050.
126 Complaint for Declaratory and Injunctive Relief, supra note 56, at 5.
127 Id.
128 id
129id
130 oid.
'" Id. at 6.
132 id.
3 Id. at 7.
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were less than optimal HLA matches because no other options
were available.13 4
MoreMarrowDonors.org ("MMD") is another of the plaintiffs
in this case and the most important for challenging NOTA. "'
MMD is a California nonprofit corporation that seeks to
incentivize bone marrow donation by providing compensation to
donors.' 3 6 MMD wants to offer $3,000 awards in the form of
scholarships, housing allowances, or charitable donations to
potential donors. 1' The program is specifically aimed at
expanding the market for hard to match individuals.' In its initial
phase, the program would only apply to minorities and mixed race
individuals because it is generally harder for them to find a suitable
match."' The idea is "that the financial incentive will induce more
potential donors to sign up, stay in touch so that they can be
located when necessary, and go through with the donations." 40
The money for these awards will be derived from third-party
philanthropists.
MMD has structured the compensation program to ease fears
that compensation will influence treatment decisions or coerce
donors. For example, MMD will have no role in matching donors
and recipients.142 Donors who want to take part in the program will
still have to sign up on a national registry. " To receive
compensation, donors must also provide a physician-signed
disclosure indicating the donor has informed the doctor of his
134 id.
1 Flynn v. Holder, 665 F.3d 1048, 1048 (9th Cir. 2011). All of the plaintiffs
in this case are associated in some way with MMD. Complaint for Declaratory
and Injunctive Relief, supra note 56, at 13. Plaintiffs Flynn, Wagner,
Majumder, and Hatchey are members of the organization. Id. Plaintiffs Hamel
and DeShay serve on MMD's board of directors. Id.
136 Flynn, 665 F.3d at 1051.
'
3 7 Id. at 1053.
138 Complaint for Declaratory and Injunctive Relief, supra note 56, at 29.
I39 id.
140 1d.
141 Id. at 28.
142 id
143 id
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intention to receive compensation.'" This disclosure also requires
the donor to provide an honest medical history.'45 Additionally, the
compensation is fixed at $3,000 and is non-negotiable.146
The plaintiffs contend that Congress included bone marrow in
NOTA by mistake.'47 They point to over 1,500 pages of legislative
history that barely mentions bone marrow. 148 Furthermore, the
plaintiffs maintain that none of the underlying interests for the
solid organ ban apply to marrow cells. ' They argue that the
precise tissue match required for a marrow transplant means that
donors are not fungible, thus inhibiting the formation of a true
market.' The plaintiffs also point to the regenerative properties of
marrow that reduce the likelihood of permanent impairment from
donation."' In addition, fixed compensation reduces concerns of
donor exploitation by avoiding donor and donee bargaining that
could lead to coercion or blackmail.152
Plaintiffs originally filed their complaint in the United States
District Court for the Central District of California. '" Judge
Valerie Fairbank dismissed the case for failure to state a claim
upon which relief could be granted.'54 The plaintiffs appealed to
the United States Court of Appeals for Ninth Circuit."'
In the complaint, the plaintiffs made two claims.'56 First, they
claimed that NOTA's ban on organ donor compensation violates
14 Id at 29.
I45 Id.
146 id.
147 id. at 32.
148 id
14 9 Id at 33.
15 0 Id Because marrow donation requires such a precise genetic match, the
number of potential buyers and sellers that could participate in an organ market
transaction is limited. Id. Plaintiffs argue that without enough participants to
bid against each other, the exploitation of poor donors by wealthy buyers is
impossible. Id.
15i Id.
152 id
Id. at 1.
154 Flynn v. Holder, 665 F.3d 1048, 1050 (9th Cir. 2011).
15 id.
15 id.
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the Equal Protection Clause because bone marrow donation is not
materially different from donating other types of renewable or
inexhaustible cells, like blood, plasma, sperm, and egg cells. '
Bone marrow donors, like other donors of renewable or
inexhaustible cells, also suffer no permanent harm, experience no
significant risk, and quickly regenerate the donated material. '8
Since these other types of donations are compensable, bone
marrow donation should be as well. 15 Second, the plaintiffs
claimed that NOTA's compensation ban violates the Due Process
clause of the Fifth Amendment. 6 0 Specifically, plaintiffs have a
liberty interest in pursuing safe, non-experimental, life-saving
treatments.' Since NOTA arbitrarily defines bone marrow as an
organ, the law is not rationally related to the pursuit of a legitimate
governmental interest.612
The government countered by arguing that NOTA plainly
classifies "bone marrow" as an organ for which compensation is
prohibited and that this Congressional determination is indeed
rational.'6 3 Congress determined that "human body parts should
not be viewed as commodities" and there are several legitimate
reasons to serve as a rational basis for the prohibition.'" With
regard to PBSCA, the government noted that bone marrow
matches are much more difficult to find than blood type matches,
which could trigger exploitative market forces.' 5 Furthermore, the
government argued PBSCA entails greater risk than blood or
plasma donation because the donor must take medicine to increase
the number of PBSCs.'6 6 Accordingly, these aspects of PBSCA
make Congress's decision to prohibit donor compensation
constitutional.
'5 Complaint for Declaratory and Injunctive Relief, supra note 56, 48-49.
158 id.
159Id.
16o ld. at 49.
161 Id.
162 Id.
163 Flynn v. Holder, 665 F.3d 1048, 1053 (9th Cir. 2011).
' Id. (quoting S. REP. No. 98-382, at 17 (1984), reprinted in 1984
U.S.C.C.A.N. 3975, 3982).
16 Id. at 1052.
166 id.
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B. The Court's Reasoning
The plaintiffs challenge NOTA's application to both methods
of BMT.' 6' First, the court addressed MMD's claim regarding
BMT via aspiration and found that it must fail. 168 NOTA
unambiguously states that bone marrow is defined as a human
organ, rendering compensation impermissible.169 The court found
that Congress did not rely on whether or not the organs could
regenerate as a criterion for judging the propriety of transplant
compensation."o Thus, it is irrelevant whether bone marrow can
regenerate like blood."'
In fact, the court pointed out that NOTA specifically prohibits
compensation for at least one organ that can regenerate, the liver.172
Developed in the 1980's, living donor liver transplant ("LDLT") is
a procedure whereby a healthy person donates part of his liver to
someone in need."' The donated tissue will grow into a new liver
for the recipient.'7 4 The donor's liver will regenerate the excised
portion within a relatively short period of time."' Because NOTA
defines an organ to include "any subpart thereof," LDLT donor
compensation is prohibited. 176 Furthermore, since the statute
expressly prohibits compensation for an organ that has the
capability to regenerate, this cannot be the rational basis for
NOTA's prohibition."
17id.
Id. at 1054.
169 id
170id
1' Id.
172 Id. at 1055.
1 DILIP MOONKA ET AL., AM. SoC'Y OF TRANSPLANTATION, LIVING DONOR
LIVER TRANSPLANTATION 2 (2007), available at http://www.a-s-t.org/files/pdf/
patient education/english/AST-EdBroGiveLiver-ENG.pdf.
174 id
as Id. Usually, the donor's liver regenerates to full size within a few days or
weeks. Id. However, the process can take up to a few months. Id. The
complication rate for the procedure is 10-25% and the risk of death is about 1 in
500. Id. at 3.
176 42 U.S.C. § 274e(c)(1) (2006).
17 Flynn, 665 F.3d at 1057.
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Next, the court explored reasons that Congress may have had
for distinguishing between compensable and non-compensable
bodily substances."' The court highlighted two types of concerns:
policy and philosophical. 7 9 From a policy standpoint, the court
speculated that Congress might have been motivated by concerns
about the exploitation of poor donors.'o Additionally, Congress
may have been worried about degrading the quality of the organ
supply by inducing people to lie about their medical history in
order to receive compensation. "' Philosophical concerns
mentioned by the court included the instinctive revulsion toward
the sale of human tissue. 182 As to which of these competing
rationales supplies the basis for NOTA's distinction, the court
reasoned:
[T]hese policy and philosophical choices are for Congress to. make, not
us. The distinctions made by Congress must have a rational basis, but
do not need to fit perfectly with that rational basis, and the basis need
merely be rational, not persuasive to all. Here, Congress made a
distinction between body material that is compensable and body
material that is not. The distinction has a rational basis, so the
prohibition on compensation for bone marrow donations by the
aspiration method does not violate the Equal Protection Clause.'8 3
The court saw this as a political question best left to the legislature.
Then, the court turned to plaintiffs' argument regarding
PBSCA.'84 In this respect, the court took a much narrower view
than MMD's proffered Equal Protection claim.'"' The court found
no need to reach such broad constitutional arguments.'8 6 Since it
did not exist at the time NOTA was passed, Congress could not
178 id.
17 9 Id. at 1056.
180Id.
181 Id. at 1055.
182 id.
18 Id. at 1056-57.
184Id. at 1057.
185id.
186 Id.
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have intended the statute to address PBSCA.'" Instead, the court
framed the question as one of statutory interpretation.'"
The court held that once PBSCs enter the bloodstream, they are
no longer part of the bone marrow, instead becoming part of the
blood itself.'" The court rejected the government's contention that
PBSCs are a subpart of the bone marrow subject to NOTA.'90 The
court stated that the government's argument would make red and
white blood cells a subpart of the bone marrow, thereby banning
compensation for blood donation."' Since NOTA is silent on the
longstanding practice of compensating blood donors and the
government concedes that such conduct is legal, such a result
could not logically follow.'92 Instead, the court narrowly construed
the term bone marrow to mean only the soft, fatty substance found
in bone cavities."' Once the cells leave the bone cavities, they
cease to be part of the bone marrow.'94 Thus, MMD will only be
able to compensate donors who undergo PBSCA, not the
traditional aspiration procedure.
V. ANALYSIS OF THE DECISION
The Flynn decision is a sensible one for several reasons. First,
the court's construction of the term bone marrow is legally correct
and a reasonable one in light of the surrounding facts. Second, the
court's narrow rationale avoided potential pitfalls inherent to
broader holdings. Lastly, PBSCA is unique when compared to the
other procedures covered by NOTA. The risks and benefits of
PBSCA are more closely matched to medical procedures for which
donor compensation is allowed, such as egg donation. By
highlighting these aspects of PBSCA in its opinion, the court may
187 Id. at 1057.
188 Id. ("We must construe the words of the statute to see what they imply
about extraction of hematopoietic stem cells by this method.").
189 id
'
90 Id. at 1058.
19' Id
192 id
'" Id.
194 id
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be beginning a policy dialogue with other branches of the
government.
A. Interpreting NOTA
The distinction drawn by the court between PBSCs and bone
marrow is the only reasonable interpretation of the term "bone
marrow" in NOTA. While stem cells play a vital role in the
marrow, they only function as part of a larger system."' Bone
marrow consists of much more than stem cells. 9 6 Furthermore,
stem cells are created and enter the bloodstream in the same
manner as all other blood cells.'97
PBSCs are not equivalent to the organ bone marrow because
they cannot perform the same function on their own. 198
Hematopoietic stem cells ("HSCs") make up a very small portion
of bone marrow. 99 It is estimated that only 1 in 10,000 bone
marrow cells is an HSC. 200 The remaining cellular tissue is
composed of mesenchymal stem cells, stromal cells, and blood
cells in various stages of maturity.201' To undergo hematopoiesis,
HSCs require an environment that provides essential growth
factors that regulate the production, differentiation, and maturation
of blood cells.2 02 This supportive environment includes barrier
cells, macrophages, and adipocytes, all served by an extensive
network of blood vessels.20 3 The marrow is also innervated by a
195 See AM. CANCER Soc'Y, supra note 40, at 4.
196 Christa E. Muller-Sieburg & Roy Riblet, Genetic Control of the Frequency
of Hematopoietic Stem Cells in Mice: Mapping of a Candidate Locus to
Chromosome 1, 183 J. EXP. MED. 1141 (1996).
197 See Gregory S. Travlos, Normal, Structure, Function, and Histology of
Bone Marrow, 34 TOXICOLOGIC PATHOLOGY 548, 549 (2006).
198 See AM. CANCER Soc'Y, supra note 40, at 4.
199 Muller-Sieburg & Roy Riblet, supra note 196, at 1141. Once an HSC
enters the bloodstream it becomes a PBSC. THE LEUKEMIA & LYMPHOMA
Soc'Y, supra note 17, at 9.
200 Sabine Hombach-Klonisch et al., Adult Stem Cells and their Trans-
Diferentiation Potential-Perspectives and Therapeutic Applications, 86 J.
MOLECULAR MED. 1301, 1304 (2008).
201 id.
202 id.
203 Travios, supra note 197, at 548.
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number of nerves. 204 In order for donated marrow to start
producing blood cells, it must engraft itself into the existing bone
marrow of the recipient.205 Only then will the marrow have the
necessary elements for hematopoiesis.206
Also, PBSCs are more like an ordinary blood cell than an organ
because they arise in a similar manner. In addition to the ability to
differentiate into any type of blood cell, HSCs can copy
themselves. 207 This provides the continuous supply of HSCs
needed to constantly produce new blood cells.208 It also means that
blood cells and PBSCs share a common heritage. Similarly, HSCs
enter the blood (becoming PBSCs) through the same process as
mature blood cells.209 Since both types of cells are created by
HSCs in the bone marrow and migrate out into the blood stream
through the same process, there is no basis to differentiate between
the two.
As the court noted in Flynn, a holding that PBSCs are the same
as bone marrow would have cast doubt on the legal status of blood
donor compensation. 210 Because of their similarities, an argument
could have been made that blood cells should be considered
equivalent to bone marrow, thus subject to NOTA. The court was
correct in avoiding this result. Since there was no doubt as to the
legality of this practice prior to Flynn, the court's holding more
effectively preserves the status quo than an opposite ruling would
have. The legal status of PBSCA donor compensation was unclear
prior to Flynn, so there is little status quo to preserve in this
respect.
B. Alternative Rationales
The Ninth Circuit had alternative grounds on which it could
have decided Flynn. In addition to ruling on either one of the
204 d
205 BE THE MATCH, supra note 24, at 13.
206 d
207 os Domen et al., Bone Marrow (Hematopoietic) Stem Cells, in NAT'L
INsTs. OF HEALTH, REGENERATIVE MEDICINE 13, 20 (2006).
208 id
209 THE LEUKEMIA & LYMPHOMA SoC'Y, supra note 17, at 5.
210 Flynn v. Holder, 665 F.3d 1048, 1058 (9th Cir. 2011).
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plaintiffs' constitutional claims, the court could have distinguished
monetary from non-monetary forms of compensation. A ruling
that NOTA bars only monetary compensation would also have
allowed MMD's program to be implemented. While these other
rationales are compelling, each has its own drawbacks.
The U.S. Supreme Court has expressed a preference for
interpreting statutes so as to avoid constitutional issues.211 Here,
the court avoided wading into the plaintiffs' constitutional
arguments by focusing instead on the narrow issue of construing
the term bone marrow. Because the Ninth Circuit's distinction
between PBSCs and bone marrow is an eminently reasonable one,
the court's action is in conformance with the Supreme Court's
view of statutory interpretation. Thus, the Ninth Circuit has
reduced the likelihood that Flynn will be overturned on appeal.
Additionally, other circuits will be more likely to adopt the Flynn
reasoning because it conforms to accepted rules of statutory
construction.
Alternatively, the court could have focused on the type of
compensation proposed by MMD. Some argue that non-monetary
consideration is an effective way to increase the supply of donors
and should be allowed under NOTA.2 12 Non-monetary forms of
compensation include: tax credits, tuition credits, job benefits, or
possibly the commutation of a prison sentence. 213 Such
compensation is viewed as more desirable because the donor does
211 Jones v. United States, 529 U.S. 848, 857 (2000); Almendarez-Torres v.
United States, 523 U.S. 224, 237-38 (1998); United States v. Jin Fuey Moy, 241
U.S. 394, 401 (1916); United States ex rel. Attorney Gen. v. Delaware &
Hudson Co., 213 U.S. 366, 408 (U.S. 1909) ("[W]here a statute is susceptible of
two constructions, by one of which grave and doubtful constitutional questions
arise and by the other of which such questions are avoided, our duty is to adopt
the latter.").
212 See David 1. Flamholtz, A Penny for Your Organs: Revising New York's
Policy on Offering Financial Incentives Organ Donation, 14 J.L. & POL'Y 329,
363 (2006).
213 DEBRA BUDIANI-SABERI & DEBORAH M. GOLDEN, AM. CONSTITUTION
Soc'Y, ADVANCING ORGAN DONATION WITHOUT COMMERCIALIZATION:
MAINTAINING THE INTEGRITY OF THE NATIONAL TRANSPLANT ACT 6 (2009),
available at http://www.cofs.org/COFS-Publications/Budiani Saberi-and
GoldenIssueBriefJune 2009.pdf.
408 [VOL. 13: 387
Bone Marrow Transplant
not receive the cash directly, reducing the likelihood that the funds
will be diverted to less desirable purposes, like gambling or
drugs. 214
The court could have used the compensation issue to avoid the
constitutional issues raised in Flynn. MMD's proposed program
contains only forms of non-monetary compensation. 2 15 By ruling
that NOTA did not apply to non-monetary compensation, the court
would have given the plaintiffs a victory in a less expansive
manner than a ruling on constitutional grounds. Instead, the court
in Flynn viewed MMD's non-monetary compensation equivalent
to cash compensation under NOTA, thus foreclosing this avenue of
216reasoning.
C. Constitutional Dialogue
Interactions between courts and the political branches of
government have sometimes been characterized as a "dialogue."217
This theory of constitutional decision-making stresses the
importance of interacting with other constitutional actors to build
consensus around important issues.2 18 The court's discussion of
NOTA's seemingly arbitrary classifications could be read as an
attempt to start a dialogue on organ donor compensation.
The one issue that continually arises in Flynn is the stark
inequity present in NOTA's classifications. The court points out
that while the doctors, nurses, and hospital all make money from
the transplant, the donor-who is at the greatest risk-is legally
barred from receiving payment.219 Likewise, procedures are treated
unequally by the law. As the court notes, egg donation
214 See Flamholtz, supra note 212, at 363.
215 Complaint for Declaratory and Injunctive Relief, supra note 56, at 9.
MMD's compensation is offered as a scholarship, housing allowance, or
charitable donation. Id.
216 Flynn v. Holder, 665 F.3d 1048, 1053 (9th Cir. 2011).
217 See generally Christine Bateup, The Dialogic Promise Assessing the
Normative Potential of Theories of Constitutional Dialogue, 71 BROOK. L. REV.
1109, 1109 (2006) (discussing the normative potential for various theories of
constitutional dialogue).
218 id
19 Id. at 1056.
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compensation is allowed under NOTA despite the significant risks
such a procedure entails.220 Furthermore, elective plastic surgery is
a long accepted practice in which people take considerable risk for
no medical benefit. The court also points out that people are
allowed to be compensated for experimental drug trials with
significant risks.22'
One way to highlight this inequity is to compare PBSCA to egg
donation. The holding in Flynn arises from the unique nature of
PBSCA. When compared to the other procedures covered by
NOTA's compensation ban, PBSCA is clearly much different from
the types of surgeries involved with donating other organs. Egg
donation and PBSCA both entail a higher level of risk than
ordinary blood donation. 222 Still, these techniques present a lower
level of risk than more invasive procedures like kidney transplants,
which are covered by NOTA.22 3
Egg donation, like PBSCA, requires donors to take drugs prior
to harvesting to increase the number of mature eggs available for
harvest.224 These drugs have risks including unpleasant side effects
and allergic reaction.225 There is even the possibility of developing
a life-threatening condition called ovarian hyperstimulation
syndrome. 226 Furthermore, the actual harvesting process is a
surgical procedure.227 To collect the eggs, doctors must insert a
small needle into the ovary follicle and remove the desired cells.228
This process is almost identical to the traditional method of bone
marrow transplant via aspiration. In fact, the procedure is called
220Id. at 1054.
221 id
222 See Bonnie Steinbock, Payment For Egg Donation and Surrogacy, 71
MOUNT SINAI J. MED. 258 (2004); see also NAT'L CANCER INST., supra note 26,
at 3.
223 42 U.S.C. § 274e(c)1 (2006).
224 N.Y. STATE TASK FORCE ON LIFE AND LAW, THINKING ABOUT BECOMING
AN EGG DONOR? GET THE FACTS BEFORE YOU DECIDE!, 6 (2009), available at
http://www.health.ny.gov/publications/1127.pdf
225 Id. at 15.226 Id. Ovarian hyperstimulation syndrome is estimated to occur in 1-10% of
cases. Steinbock, supra note 222.
227 N.Y. STATE TASK FORCE ON LIFE AND LAW, supra note 224, at 17.
228 id
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transvaginal ovarian aspiration. 229 The only difference is that the
ovaries can be accessed transvaginally, whereas an incision must
be made to aspirate the bone marrow.230
Egg donation has been allowed for many years with little
regulatory oversight. The tolerance for this procedure is grounded
in an implicit risk-benefit analysis. The risks from egg donation
are acceptable considering the gift others stand to receive.
Because of the parallels between egg donation and PBSCA,
society could accept marrow donor compensation as well. By
pointing out the inconsistency with which NOTA treats procedures
of commensurate risk, the court could be signaling its specific
concerns about the law to the political branches. Congress can
address these concerns and start to build a constitutional consensus
regarding just what procedures should be covered by NOTA. This
type of dialogue may be more conducive to achieving stable organ
donor policies than unilateral judicial decision-making in the long
run.
VI. IMPLICATIONS FOR ORGAN TRANSPLANTATION
Because Flynn now allows for donor compensation, the results
of programs like MMD's are likely to influence the debate over
future organ donor compensation policies. The failure of these
programs may lead to the curtailment of future efforts to broaden
donor compensation. Likewise, any success could shift the policy
focus towards a market-oriented approach. Going forward,
supporters and opponents of organ donor compensation should
closely observe MMD's program to see what lessons can be
learned. The success of the program remains to be seen, but if
other donor compensation schemes are an accurate predictor,
patient outcomes will improve. The best way to predict the effects
of Flynn is to look to analogous situations in other countries.
Iran instituted a direct compensation program for live kidney
donors in 1988."' The program is administered through a non-
229 id
230id
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profit entity similar to NMDP in the United States. 23 2 "Donors
receive $1,200 from the government and one year of free
healthcare from the government, along with a payment from the
organ recipient, generally ranging from $2,300 to $4,500.""' In
cases where the recipient cannot afford to pay, a charitable
organization will provide compensation to the donor.2 34  This
program has eliminated the kidney waiting list in Iran."'
More recently, Israel has launched several new policies aimed
at increasing the number of organ donors.236 Israel has long
suffered from low donation rates at death.237 In 2008, Israel passed
a de facto legalization of compensation for the families of deceased
organ donors.238 The law allowed families of posthumous donors
to receive up to $13,400 to memorialize. their loved ones.239 Israel
also passed a law that granted priority status to people who register
231 Ahad J. Ghods & Shekoufeh Savaj, Iranian Model of Paid and Regulated
Living-Unrelated Kidney Donation, CLIN. J. AM. Soc. NEPHROLOGY 1136, 1137
(2006).
232 JENNIFER MONTI, COMPETITIVE ENTERPRISE INST., THE CASE FOR
COMPENSATING LIVE ORGAN DONORS 9 (2009), available at
http://cei.org/sites/default/files/Jennifer%20Monti%2-%20OThe%2OCase%20for
%20Compensating%2OLive%200rgan%20Donors.pdf.
233 d
234 d
235 Ghods &.Savaj, supra note 231, at 1139. Between 1988 and 2005, 19,609
kidney transplants had been performed in Iran. Id. This compares to roughly
12,000 performed in the United States in 2011 alone. Transplant Trends,
UNITED NETWORK FOR ORGAN SHARING, http://www.unos.org/ (last visited Feb.
26, 2012). It has been suggested that many rural Iranians with kidney problems
do not get diagnosed properly. Id. This may have contributed to the speedy
elimination of the kidney waiting list. Id.
236 Sally Satel, Kidney Mitzvah Israel's remarkable new steps to solve its
organ shortage, SLATE 1 (Jan. 27, 2010, 4:47 PM) http://www.slate.com/
articles/health and science/medical examiner/2010/01/kidney mitzvah.html.
237 Id. Israel's rate of deceased donation is around nine donors per one million
people. Id. This compares to twenty-five donors per one million people in the
United States. Id. Some commentators have speculated that this disparity is due
to the mistaken belief that Jewish law requires the body to be buried whole. Id.
238 Dan Even, Dramatic increase in organ transplants recorded in Israel in
2011, HAARETZ.COM (Dec. 1, 2012, 1:03 PM), http://www.haaretz.com/print-
edition/news/dramatic-increase-in-organ-transplants-recorded-in-israel-in-2011-
1.406824.
239 Satel, supra note 236, at 1.
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to donate their organs upon death. 240 All things being equal, a
registered donor who is in need of an organ will receive it over a
patient who is not registered.24'
Similarly, Israel has also instituted policies aimed at increasing
the supply of live donors.242 In August 2010, living donors began
receiving compensation for proven expenses associated with the
transplant. 243 These expenses include lost wages, transportation,
and insurance. 2 4 Lastly, Israel introduced a program called the
"chain of living donors." 245  This program allows relatives of
people on the kidney waiting list to donate a kidney to someone
else.246 In exchange, the donor's relative is given priority for a new
kidney.247
The results of these new policies have been overwhelming.
The total number of organ transplants increased 68% in 2011.248
Kidney transplants from living donors increased from just over 70
in 2010 to 117 in 2011, an increase of 64%.249 The number of
kidneys, hearts, and livers received from deceased donors each
more than doubled the previous year's totals.250 Additionally, the
number of organ donor signatures increased by over 12%.251
One issue that remains to be settled is how the existing organ
transplantation infrastructure will co-exist with marrow donor
compensation programs. A coalition of organizations, including
NMDP and the World Marrow Donor Society, has formed in
opposition to the Flynn decision.25 2 They are concerned that
240 id
241 id.
242 Even, supra note 238.
243 id.244 id.
245 Id.
246 d
247 Id
248 Id.
249 id
250 id
251 id
252 Leading Global Cell Therapy Organizations Support, NAT'L MARROW
DONOR PROGRAM (Feb. 2, 2012), http://marrow.org/News/News Releases/2012/
Leading GlobalCellTherapy Organizations Support.aspx.
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compensation programs could actually decrease the supply of
donors in a couple of ways.253
First, compensation might reduce motivation of altruistic
donors.2 54 One study witnessed a similar phenomenon in blood
donors.255 It found that when blood donors were given a surprise
monetary gift of $5-15 after their donation, they were less likely to
donate afterward.256 Secondly, NMDP asserts that Flynn could
adversely affect the supply of marrow in other jurisdictions by
creating an expectation of compensation. 257 The same study
mentioned above found that there was a comparable effect noticed
amongst blood donors.25 8 Donation centers offering compensation
attracted donors away from other centers.2 59 However, the study
found that the overall effect of the compensation made donations
increase, despite these negative effects.260 Much of this increase
was due to donors who recruited additional donors because of the
compensation offer.26'
Although blood donation and PBSCA are not completely
identical, the data presented in the study may be a good proxy for
predicting the effects of donor compensation on existing marrow
donor organizations. NMDP and other organizations should not
worry for the time being about declining registration. MMD's
program requires donors to sign up at an organization like
NMDP.262 In the future, other organizations may choose to operate
253 Id.
254 NMDP Opposes Ninth Circuit Court Ruling on PBSC Donor
Compensation, NAT'L MARROW DONOR PROGRAM (Dec. 5, 2011),
http://marrow.org/News/News Releases/2011/NMDP Opposes Ninth Circuit
Court Ruling on PBSC Donor Compensation.aspx.
255 Nicola Lacetera et al., Rewarding Altruism? A Natural Field Experiment 2
Nat'1 Bureau of Econ. Research Working Paper Series, Paper No. 17636 (2011),
available at http://www.nber.org/papers/w 17636.
256 id
257 NMDP Opposes Ninth Circuit Court Ruling on PBSC Donor
Compensation, supra note 254.
258Lacetera et al., supra note 255, at 4.
259 id..
260 Id. at 2.
261 id.
262 Complaint for Declaratory and Injunctive Relief, supra note 56, at 28.
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a registry concurrently with a compensation program. This could
lead to a reduction in donors registering with NMDP.
VII. CONCLUSION
As a case interpreting the meaning of NOTA and the interests
underlying it, the Flynn decision provides an interesting lens
through which to view broader donation policy. The success of
any transplant therapy is inevitably tied to its ability to attract
suitable donors. In Flynn, the Ninth Circuit took an important first
step in allowing new ways to incentivize organ donation.
Furthermore, this ruling presents an excellent opportunity to
stimulate the organ donor compensation debate and re-examine
how the rationale behind NOTA comports with today's world.
Although the result is less broad than what the plaintiffs sought,
the end result may prove to be more impactful on the future of
organ donation. The limited and straightforward manner of the
Ninth Circuit's opinion makes it more likely than alternative
rationales to be adopted by other courts. It provides a simple, clear
roadmap for excluding PBSCA from NOTA's compensation ban.
A more expansive ruling on constitutional grounds might have
provoked a backlash from other Circuits, a reversal by the
Supreme Court or legislative action.
On March 27 th, 2012, the Ninth Circuit denied the
government's request for rehearing. 263 "No future petitions for
rehearing or rehearing en banc will be entertained."21 Senior
Circuit Judge Andrew Kleinfeld amended the original opinion to
address a new argument made by the government in its petition for
rehearing. 26 5 According to the state, Congress has defined "bone
marrow" to include PBSCs in at least one other statute, therefore it
must have attached the same meaning to "bone marrow" in
NOTA. 266 The court was not persuaded by this reasoning in the
least, saying that "[t]his new argument by the government, like its
263 Flynn v. Holder, No. 10-55643, 2012 U.S. App. LEXIS 6254, at *5 (9th
Cir. Mar. 27, 2012).
2 64 id.
2651 d at *1
266 1d. at *2.
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old arguments, cannot be reconciled with the government's
concession that the National Organ Transplant Act does not
prohibit buying blood." 267
The Flynn ruling seems safe for the time being. Congress has
not indicated any interest in amending NOTA to specifically
include PBSCA. Moreover, while the HHS Secretary has the
power to classify PBSC's as an organ, there has been no indication
of this yet. The court noted that should an HHS Secretary exercise
her authority to classify PBSC's as an organ in the future, it may
have to delve into the plaintiffs constitutional arguments. 268
Perhaps MMD's compensation program will prove to be an
enormous success obviating the need to revisit this decision. Only
time will tell.
267 Id. at *4.
268 Flynn v. Holder, 665 F.3d 1048, 1058 (9th Cir. 2011).
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